A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol OAD Tablets to Twice Daily Tramadol BID for the Treatment of Osteoarthritis of the Knee (Extension Protocol) and Open Label Safety Follow-Up

NCT ID: NCT00912015

Last Updated: 2012-04-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 238 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2002-03-31
• Study Completion Date: 2003-07-31

Brief Summary

The purpose of this study is to evaluate the long-term safety (up to one year) of Tramadol Once-A-Day (OAD) tablets at the highest doses: 200-400 mg

Conditions

Pain; Osteoarthritis, Knee

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Tramadol OAD 200mg

Group Type: EXPERIMENTAL

Tramadol OAD

Intervention Type: DRUG

Tramadol OAD 300mg

Group Type: EXPERIMENTAL

Tramadol OAD

Intervention Type: DRUG

Tramadol OAD 400mg

Group Type: EXPERIMENTAL

Tramadol OAD

Intervention Type: DRUG

Tramadol OAD 100mg

Despite provision in the protocol that the minimum daily dose was 200 mg, 2 patients took 100 mg against instructions.

Group Type: OTHER

Tramadol OAD 100mg

Intervention Type: DRUG

Interventions

Tramadol OAD

Intervention Type: DRUG

Tramadol OAD

Intervention Type: DRUG

Tramadol OAD

Intervention Type: DRUG

Tramadol OAD 100mg

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or Female patients between the ages of 40-75 with a diagnosis of Osteoarthritis of the knee consistent with the ACR Clinical Classification Criteria for Arthritis of the Knee (Altman, R. et al., 1991):

• Current knee pain,
• Less than 30 minutes of morning stiffness with or without crepitus on active motion.
• Confirmation either by arthroscopy or radiologist's report (X-rays showing osteophytes, joint space narrowing or subchondral bone sclerosis {eburnation}) within one year prior to entry into the study.

2. ESR < 40 mm/hour

3. WOMAC Pain Subscales total score of more than or equal to 150 mm at baseline.

4. Oral and written language comprehension at a level sufficient to comply with the protocol and complete study-related materials.

5. The Patient has signed and dated the REB approved, written, informed consent prior to study participation.

Exclusion Criteria

1. Known rheumatoid arthritis or any other rheumatoid disease.

2. Secondary arthritis, i.e. any of the following: septic arthritis; inflammatory joint disease; gout; pseudogout; Paget's disease; joint fracture; acromegaly; fibromyalgia; Wilson's disease; Ochronosis; Haemochromatosis; Osteochondromatosis; heritable arthritic disorders; or collagen gene mutations.

3. Obesity Class II (BMI more than or equal to 35) (NIH, 2000)

4. Major illness requiring hospitalization during the 3 months before commencement of the screening period.

5. Unwillingness to cease taking medication other than the study medication for arthritic pain, any other concomitant pain, or OA medications.

6. Patients who have previously failed tramadol HCl therapy or those who discontinued tramadol HCl due to adverse events.

7. Patients who are taking or within the last 3 weeks have taken the following medications: monoamine oxidase inhibitors; tricyclic antidepressants and other tricyclic compounds (e.g. cyclobenzaprine, promethazine); neuroleptics; selective serotonin reuptake inhibitors; or other drugs which reduce seizure threshold.

8. Patients who are taking or have taken another investigational agent within the last 30 days.

9. Patients with a history of seizure disorder other than Infantile Febrile Seizures.

10. Patients who are opioid dependent.

11. Patients with bowel disease causing malabsorption.

12. Patients who are pregnant or lactating or patients of child-bearing potential who are unwilling to utilize a medically approved method of contraception during participation in this clinical trial.

13. Patients with significant liver disease, defined as active hepatitis or elevated liver enzymes >3 times the upper boundary of the normal range.

14. Patients with significant renal disease, defined as creatinine clearance <30 mL/min as estimated by the method of Levey et al., 1999.

15. Current substance abuse or dependence, other than nicotine.

16. Allergy or adverse reaction to tramadol or any structurally similar drugs e.g. opiates.

17. Any other condition that, in the opinion of the investigators, would adversely affect the patient's ability to complete the study or its measures.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Labopharm Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

NCT00912015

Identifier Type: REGISTRY

Identifier Source: secondary_id

MDT3-001-E1-A1

Identifier Type: -

Identifier Source: org_study_id